ChromaDex Launches Niagen+ NAD+ Test Kit Available Exclusively To Health Care Practitioners
Portfolio Pulse from Benzinga Newsdesk
ChromaDex Corp. (NASDAQ:CDXC) has launched the Niagen+ NAD+ Test Kit, available exclusively to healthcare practitioners. This kit allows practitioners to measure patient blood NAD+ levels, aiding in the creation of personalized treatment protocols using ChromaDex's NAD+-boosting products.
July 23, 2024 | 12:38 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ChromaDex Corp. has introduced the Niagen+ NAD+ Test Kit, which is available exclusively to healthcare practitioners. This product launch could enhance the company's market position in the healthcare sector by providing a unique tool for personalized patient care.
The launch of the Niagen+ NAD+ Test Kit is a significant development for ChromaDex as it provides a new product exclusively for healthcare practitioners. This could lead to increased adoption of ChromaDex's NAD+-boosting products, potentially driving revenue growth and enhancing the company's market position.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100